Anti-diabetic efficacy and selective inhibition of methyl glyoxal, intervention with biogenic Zinc oxide nanoparticle

Abstract

Non-enzymatic glycation of biomolecules results in advanced glycation end products (AGEs), which are responsible for secondary complications in diabetes. Inhibiting methyl glyoxal (MGO) induced advanced glycation end product (AGE) formation is the only way to alleviate diabetic complications. This study aimed to look into the abilities of herbal extract Kigelia africana and K. africana synthesized zinc oxide nanoparticles (ZnONPs) to inhibit the emergence of MG-derived AGEs. The study intended to determine antioxidant and AGE inhibition of the plant extract and ZnONPs. ZnONPs were tested for the efficiency of anti-diabetic activity in streptozotocin-induced diabetic Wister rats. We discovered that the MGO-trapping effects on the prevention of AGE production were mediated by the downregulation of the amplification of MGO-trapping impacts on the hypoglycemic and antihyperlipidemic mechanisms of ZnONPs. According to histological findings, the treatment with ZnONPs also successfully lowers inflammation in the hepatic and renal tissues. Overall, future mechanistic research could establish ZnONPs potential anti-diabetic properties.